Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.

Carol H WyshamJulio RosenstockMarion L VetterFang DongPeter ÖhmanNayyar Iqbal

Published in: Diabetes, obesity & metabolism (2017)

Exenatide QWS-AI was associated with a greater reduction in HbA1c, similar weight loss and a favorable gastrointestinal AE profile compared with exenatide BID.

Keyphrases

weight loss
bariatric surgery
physical activity
artificial intelligence
open label
type diabetes
clinical trial
machine learning
adipose tissue
skeletal muscle
double blind
deep learning
weight gain